title: Translating the molecular diversity of hepatocellular carcinoma into clinical practice.
abstract: Deciphering genomic diversity could improve clinical care for patients with hepatocellular carcinoma. Recently, our study group identified 161 putative driver genes and 2 new mutational signatures, and demonstrated that 28% of patients harbor targetable alterations. This could be the first promising step in the development of genome-based clinical trials.
authors.affiliation: Inserm, UMR-1162, Génomique fonctionnelle des Tumeurs solides, Equipe Labellisée Ligue Contre le Cancer, Institut Universitaire d'Hématologie, Paris, France; Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Université Paris 13, Bobigny, France; Université Paris Diderot, Paris, France.
authors.forename: Kornelius
authors.initials: K
authors.lastname: Schulze
authors.affiliation: Inserm, UMR-1162, Génomique fonctionnelle des Tumeurs solides, Equipe Labellisée Ligue Contre le Cancer, Institut Universitaire d'Hématologie, Paris, France; Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Université Paris 13, Bobigny, France; Université Paris Diderot, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Jessica
authors.initials: J
authors.lastname: Zucman-Rossi
keywords: ARID1A (AT rich interactive domain 1A); AXIN1 (axin 1); Aflatoxin B1; CTNNB1 (catenin ?); TERT (telomerase reverse transcriptase); TP53 (tumor protein p53); cancer driver genes; disease stage; exome sequencing; genome-based clinical trials; genomics; hepatocellular carcinoma (HCC); mutational signatures; overall survival; risk factors